Technology
Health
Biotechnology

Blueprint Medicines

$78.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$5.89 (-6.97%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BPMC and other stocks, options, ETFs, and crypto commission-free!

About

Blueprint Medicines Corporation Common Stock, also called Blueprint Medicines, is a precision therapy company, which focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Read More Lydon, Brian Druker, and Alexis Borisy in October 2008 and is headquartered in Cambridge, MA.

Employees
217
Headquarters
Cambridge, Massachusetts
Founded
2008
Market Cap
3.46B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
410.56K
High Today
$84.51
Low Today
$78.28
Open Price
$83.97
Volume
307.97K
52 Week High
$103.12
52 Week Low
$44.58

Collections

Technology
Health
Biotechnology
Therapy
Cancer Prevention
2015 IPO
US
North America

News

Seeking AlphaFeb 25

Blueprint Medicines Q4 2018 Earnings Preview

Blueprint Medicines (NASDAQ:BPMC) is scheduled to announce Q4 earnings results on Tuesday, February 26th, before market open. The consensus EPS Estimate is -$1.76 (-43.1% Y/Y) and the consensus Revenue Estimate is $1.69M (+3.7% Y/Y). Over the last 2 years, BPMC has beaten EPS estimates 63% of the time and has beaten revenue estimates 88% of the time....

309

Earnings

-$1.83
-$1.43
-$1.02
-$0.62
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.